Baseline versus on-treatment heart failure with preserved ejection fraction in a real world cardio-oncology setting: observational analysis of cardiotoxicity and cancer treatment implications

Clicks: 1
ID: 323280
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #174 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background The prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) increases due to improved diagnostic tools and treatments. In cancer patients undergoing potentially cardiotoxic treatments, HFpEF is not included in baseline risk stratification, nor in cancer therapy-related cardiac dysfunction (CTRCD) definitions. Data on HFpEF in this population are scarce. Purpose We described baseline HFpEF prevalence in cancer patients, and compared the incidence of cardiotoxic and HF events (CTRCD + HFpEF decompensation) and mortality in this subgroup compared to patients without pre-existing HF and to patients with pre-existing HF(m)rEF. Secondly, we investigated the incidence of HFpEF events (new HFpEF diagnosis or decompensation of pre-existing HFpEF) during or after cancer therapy, identifying predictors for developing on-treatment HFpEF. Methods & Results This observational, retrospective real-world analysis included 665 patients (54.1% female, mean age 62.1 years, median follow-up 485 days), of whom 36 (5.4%) had known HFpEF prior to cancer therapy initiation. In this subgroup, 19/36 (52.8%) developed cardiotoxic events, 16/36 (44.4%) developed HF events and 10/36 (27.8%) died. Independent of baseline characteristics, 96/665 patients (14.4%) developed HFpEF events, of whom 46/96 (47.9%) had pre-existing CVD yet only 15/96 (15.6%) a previous HFpEF diagnosis. Cancer therapy required adaptation in 12/96 patients (12.5%). Older age, female sex, arterial hypertension and previous arrhythmias predicted on-treatment HFpEF events in multivariate analysis. Conclusion Pre-existing HFpEF carries a significant cardiotoxicity and mortality risk comparable to HF(m)rEF, but is likely underdiagnosed in cancer patients. On-treatment HFpEF events are common and may have important cancer treatment (and prognosis) implications. . Risk predictors for HFpEF events during or after cancer therapy are female sex, symptom referral, age >65 years, AHT, pre-existing arrhythmia and immunomodulatory myeloma therapy. Further investigations are required to evaluate whether specific management strategies may improve prognosis in these patientsGraphic Abstract
Reference Key
openalex_W7172331339 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors B Von Kemp, X Galloo, B Roosens, B Neyns, R Schots, M De Ridder, B Cosyns
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.045
URL
https://doi.org/10.1093/eurheartjsupp/suag097.045
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.